Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
作者
Josep M. Tabernero,Axel F. Grothey,Eric Van Cutsem,Rona D. Yaeger,Harpreet Singh Wasan,Takayuki Yoshino,Jayesh Desai,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik‐Tobias Arkenau,Pilar García Alfonso,Ashwin M. Gollerkeri,Michael D. Pickard,Kati S. Maharry,Janna Christy‐Bittel,Lisa Anderson,Scott Kopetz